StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
NEUPNeuphoria Therapeutics Inc.
stockpulse.co.kr
Nasdaq
$3.42▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $18.5MShares out 5.4M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

7
  • 1d agoPre-market26.10.23 21:00
    8-KKey event#●●●

    Neuphoria Therapeutics Inc.

    Neuphoria Therapeutics entered into Amendment No. 1 to its Rights Agreement on October 23, 2026, extending the Final Expiration Date of the original agreement from October 2025 to October 27, 2027. This action effectively extends the duration of the company's existing shareholder rights plan, commonly known as a poison pill.…more

    $3.42+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.5Regular26.10.05 22:41
    SCHEDULE 13GOwnership

    Neuphoria Therapeutics Inc.

    AdvisorShares Trust has filed a Schedule 13G with the SEC, reporting its beneficial ownership in Neuphoria Therapeutics Inc. This filing formalizes the institutional investor's position as a significant shareholder in the company.…more

    $3.42+0.00%vs prev close
    View filingShare
  • 9.18After-hours26.09.19 06:12
    DEFA14AOther

    Neuphoria Therapeutics Inc.

    Neuphoria Therapeutics Inc. has filed additional proxy solicitation materials (DEFA14A) regarding its upcoming shareholder meeting. This filing is intended to provide supplementary information for meeting agenda items and does not contain any changes to the company's financial status or capital structure.…more

    $3.42+0.00%vs prev close
    View filingShare

6 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.18After-hours26.09.19 06:26
    Bullish#●●●

    Neuphoria Therapeutics Q4 Earnings Miss Estimates

    Neuphoria Therapeutics reported a Q4 loss of $0.95 per share, missing the analyst consensus estimate of $0.56. While the company generated $1.174 million in revenue, the increased losses indicate a disappointing quarterly performance.…more

    $3.42+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga